Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV observational database

Jialun Zhou, N. I. Paton, R. Ditangco, Y. M.A. Chen, A. Kamarulzaman, N. Kumarasamy, C. K.C. Lee, P. C.K. Li, F. Yuliana, P. Phanuphak, S. Pujari, A. Vibhagool, F. Zhang, J. Chuah, K. R. Frost, D. A. Cooper, M. G. Law, C. V. Mean, V. Saphonn, F. ZhangH. Zhao, N. Han, P. Li, M. P. Lee, N. Kumarasamy, J. A. Cecelia, K. Joshi, F. Yuliana, S. Oka, M. Honda, J. Pang, R. Capistrano, W. W.Y. Wong, R. Chang, P. L. Lim, C. K.C. Lee, S. M. Thitsar, M. Khongphattanayothing, S. Kiertiburanakul, W. Kiatatchasai, T. Sirianthana

研究成果: 雜誌貢獻文章同行評審

48 引文 斯高帕斯(Scopus)

摘要

Background: The antiretroviral treatment (ART) combination of stavudine, lamivudine and nevirapine (d4T/3TC/NVP) is the most frequently used initial regimen in many Asian countries. There are few data on the outcome of this treatment in clinic cohorts in this region. Methods: We selected patients from the TREAT Asia HIV Observational Database (TAHOD) who started their first ART regimen with d4T/3TC/NVP. Treatment change was defined as cessation of therapy or the addition or change of one or more drugs. Clinical failure was defined as diagnosis with an AIDS-defining illness, or death while on d4T/3TC/NVP treatment. Results: The rate of treatment change among TAHOD patients starting d4T/3TC/NVP as their first antiretroviral treatment was 22.3 per 100 person-years, with lower baseline haemoglobin (i.e. anaemia) associated with slower rate of treatment change. The rate of clinical failure while on d4T/3TC/NVP treatment was 7.3 per 100 person-years, with baseline CD4 cell count significantly associated with clinical failure. After d4T/3TC/ NVP was stopped, nearly 40% of patients did not restart any treatment and, of those who changed to other treatment, the majority changed to zidovudine (ZDV)/3TC/NVP and less than 3% of patients changed to a protease inhibitor (PI)-containing regimen. The rates of disease progression on the second-line regimen were similar to those on the first-line regimen. Conclusion: These real-life data provide an insight into clinical practice in Asia and the Pacific region. d4T/3TC/NVP is maintained longer than other first-line regimens and change is mainly as a result of adverse effects rather than clinical failure. There is a need to develop affordable second-line antiretroviral treatment options for patients with HIV infection in developing countries.
原文英語
頁(從 - 到)8-16
頁數9
期刊HIV Medicine
8
發行號1
DOIs
出版狀態已發佈 - 1月 1 2007
對外發佈

ASJC Scopus subject areas

  • 健康政策
  • 傳染性疾病
  • 藥學(醫學)

指紋

深入研究「Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV observational database」主題。共同形成了獨特的指紋。

引用此